{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T19:06:03Z","timestamp":1784833563776,"version":"3.55.0"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Danish NF Patient Association NF Danmark"},{"name":"Max W\u00f8rzner and Inger W\u00f8rzner\u2019s memorial trust and the Dagmar Marshall Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>While neurofibromatosis type 1 (NF1)-associated malignant peripheral nerve sheath tumor (nfMPNST) is often considered to have a particularly poor prognosis compared to sporadic malignant peripheral nerve sheath tumor (sMPNST), this assumption remains insufficiently substantiated. This study aimed to compare clinical characteristics, treatment outcome, and survival between nfMPNST and sMPNST in a nationwide Danish cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient and method<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of patients with malignant peripheral nerve sheath tumor (MPNST) in Denmark from 2000 to 2020. NF1-associated cases were identified through a national NF1 registry, while sporadic cases of MPNST were extracted from the Danish Sarcoma Database. Clinical, pathological, and treatment data were supplemented by chart review and national pathology records. Survival outcomes were analyzed using Kaplan\u2013Meier estimates and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 146 patients were included, of which 42 had nfMPNST and 104 sMPNST. Patients with nfMPNST were significantly younger at diagnosis (median 37 [min-max: 12-73] vs 58 [min-max: 5-93] years, P\u2009&amp;lt;\u2009.001) and had larger tumors (&amp;gt;5\u2009cm in 88% vs 50%, P\u2009&amp;lt;\u2009.001). Wide margin resection was achieved less often in nfMPNST (35% vs 66%, P\u2009=\u2009.003), and adjuvant radiotherapy was more commonly administered (61% vs 36%). Five-year overall survival for localized disease was significantly lower in nfMPNST (44% vs 63%, P\u2009=\u2009.03), with higher recurrence rates (69% vs 49%, P\u2009=\u2009.049) and shorter time to recurrence (median 2.2 vs 3.4\u2009years). Among 27 sMPNST tumors analyzed by next-generation sequencing, 5 (19%) harbored pathogenic NF1 variants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>nfMPNST presents at a younger age with more aggressive features and worse outcomes compared to sporadic cases. These findings support the need for tailored surveillance and treatment strategies in NF1 patients and highlight the potential role of NF1 alterations in sMPNST pathogenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag255","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:22:31Z","timestamp":1783081351000},"source":"Crossref","is-referenced-by-count":0,"title":["Prevalence, treatment and survival of malignant peripheral nerve sheath tumor in the Danish neurofibromatosis type 1 population"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6859-5296","authenticated-orcid":false,"given":"Ninna","family":"Aggerholm-Pedersen","sequence":"first","affiliation":[{"name":"Department of Oncology, Sarcoma Centre of Aarhus University Hospital , Aarhus N, 8200,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette M\u00f8ller","family":"Handrup","sequence":"additional","affiliation":[{"name":"Centre for Rare Diseases, Pediatrics and Adolescent Medicine , Aarhus N, 8200,","place":["Danmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine Bogestofte","family":"Thomassen","sequence":"additional","affiliation":[{"name":"Centre for Rare Diseases, Pediatrics and Adolescent Medicine , Aarhus N, 8200,","place":["Danmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodil","family":"Engelmann","sequence":"additional","affiliation":[{"name":"Department of Oncology , Copenhagen University Hospital, Herlev, 2730,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja Maretty","family":"Kongstad","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sarcoma Center of Aarhus University Hospital , Aarhus N, 8200,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vad","family":"Jakobsen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Sarcoma Center of Aarhus University Hospital , Aarhus N, 8200,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Baad-Hansen","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, Sarcoma Center of Aarhus University Hospital , Aarhus N, 8200,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stense","family":"Farholt","sequence":"additional","affiliation":[{"name":"Department of Pediatric and Adolescent Medicine, Centre for Rare Diseases, Copenhagen University Hospital\u2014Rigshospitalet , Copenhagen, 2100,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Thomas","sequence":"additional","affiliation":[{"name":"Centre for Molecular Oncology, University of New South Wales , NSW, 2052,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilie","family":"Ejerskov","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sarcoma Centre of Aarhus University Hospital , Aarhus N, 8200,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"2026072314213822800_oyag255-B1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3109\/17453674.2014.908341","article-title":"Prognostic factors for local recurrence and mortality in adult soft tissue sarcoma of the extremities and trunk wall: a cohort study of 922 consecutive patients","volume":"85","author":"Maretty-Nielsen","year":"2014","journal-title":"Acta Orthop"},{"key":"2026072314213822800_oyag255-B2","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/cncr.28657","article-title":"Sarcoma classification: an update based on the 2013 world health organization classification of tumors of soft tissue and bone","volume":"120","author":"Doyle","year":"2014","journal-title":"Cancer"},{"key":"2026072314213822800_oyag255-B3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12957-020-02036-x","article-title":"Prognosis and risk factors for malignant peripheral nerve sheath tumor: a systematic review and meta-analysis","volume":"18","author":"Cai","year":"2020","journal-title":"World J Surg Oncol"},{"key":"2026072314213822800_oyag255-B4","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/cncr.22098","article-title":"Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution","volume":"107","author":"Anghileri","year":"2006","journal-title":"Cancer"},{"key":"2026072314213822800_oyag255-B5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"Evans","year":"2002","journal-title":"J Med Genet"},{"key":"2026072314213822800_oyag255-B6","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13023-023-02911-2","article-title":"Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysis","volume":"18","author":"Lee","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"2026072314213822800_oyag255-B7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.2340\/0001555575136140","article-title":"Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in g\u00f6teborg, Sweden","volume":"75","author":"Z\u00f6ller","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"2026072314213822800_oyag255-B8","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1056\/NEJM198604173141603","article-title":"Long-term follow-up of von recklinghausen neurofibromatosis. Survival and malignant neoplasms","volume":"314","author":"S\u00f8rensen","year":"1986","journal-title":"N Engl J Med"},{"key":"2026072314213822800_oyag255-B9","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1086\/320121","article-title":"Mortality in neurofibromatosis 1: an analysis using U.S. death certificates","volume":"68","author":"Rasmussen","year":"2001","journal-title":"Am J Hum Genet"},{"key":"2026072314213822800_oyag255-B10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11912-009-0045-z","article-title":"Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors","volume":"11","author":"Widemann","year":"2009","journal-title":"Curr Oncol Rep"},{"key":"2026072314213822800_oyag255-B11","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1093\/neuonc\/noy013","article-title":"The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors","volume":"20","author":"Higham","year":"2018","journal-title":"Neuro Oncol"},{"key":"2026072314213822800_oyag255-B12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.radonc.2019.03.015","article-title":"Radiation-induced and neurofibromatosis-associated malignant peripheral nerve sheath tumors (MPNST) have worse outcomes than sporadic MPNST","volume":"137","author":"Miao","year":"2019","journal-title":"Radiother Oncol"},{"key":"2026072314213822800_oyag255-B13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2019.10.014","article-title":"A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumours","volume":"124","author":"Martin","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026072314213822800_oyag255-B14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.oraloncology.2019.09.010","article-title":"Malignant peripheral nerve sheath tumors: analysis of the national cancer database","volume":"98","author":"Mowery","year":"2019","journal-title":"Oral Oncol"},{"key":"2026072314213822800_oyag255-B15","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1179\/joc.2010.22.6.413","article-title":"High grade malignant peripheral nerve sheath tumors: outcome of 62 patients with localized disease and review of the literature","volume":"22","author":"Longhi","year":"2010","journal-title":"J Chemother"},{"key":"2026072314213822800_oyag255-B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ejca.2015.12.015","article-title":"Management and prognosis of malignant peripheral nerve sheath tumors: the experience of the french sarcoma group (GSF-GETO)","volume":"56","author":"Valentin","year":"2016","journal-title":"Eur J Cancer"},{"key":"2026072314213822800_oyag255-B17","doi-asserted-by":"publisher","first-page":"104785","DOI":"10.18632\/oncotarget.18975","article-title":"Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: a retrospective study of 159 cases from 1999 to 2016","volume":"8","author":"Yuan","year":"2017","journal-title":"Oncotarget"},{"key":"2026072314213822800_oyag255-B18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s40487-022-00213-4","article-title":"Clinical characteristics and management of children and adults with neurofibromatosis type 1 and plexiform neurofibromas in Denmark: a nationwide study","volume":"11","author":"Ejerskov","year":"2023","journal-title":"Oncol Ther"},{"key":"2026072314213822800_oyag255-B19","doi-asserted-by":"publisher","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","article-title":"Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020","volume":"4","author":"Landry","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2026072314213822800_oyag255-B20","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/1471-2407-14-682","article-title":"Relative mortality in soft tissue sarcoma patients: a danish population-based cohort study","volume":"14","author":"Maretty-Nielsen","year":"2014","journal-title":"BMC Cancer"},{"key":"2026072314213822800_oyag255-B21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/01.blo.0000131256.82455.c5","article-title":"Survival data for patients with malignant schwannoma","author":"Cashen","year":"2004","journal-title":"Clin Orthop Relat Res"},{"key":"2026072314213822800_oyag255-B22","doi-asserted-by":"publisher","first-page":"756395","DOI":"10.1155\/2009\/756395","article-title":"Survival in malignant peripheral nerve sheath tumours: a comparison between sporadic and neurofibromatosis type 1-Associated tumours","volume":"2009","author":"Porter","year":"2009","journal-title":"Sarcoma"},{"key":"2026072314213822800_oyag255-B23","doi-asserted-by":"publisher","first-page":"e28138","DOI":"10.1002\/pbc.28138","article-title":"Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: a nationwide cohort study","volume":"67","author":"Martin","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2026072314213822800_oyag255-B24","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/neuonc\/nos287","article-title":"Survival meta-analyses for &gt;1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1","volume":"15","author":"Kolberg","year":"2013","journal-title":"Neuro Oncol"},{"key":"2026072314213822800_oyag255-B25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12957-023-03296-z","article-title":"Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis","volume":"22","author":"Lim","year":"2024","journal-title":"World J Surg Oncol"},{"key":"2026072314213822800_oyag255-B26","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1158\/1078-0432.CCR-22-3722","article-title":"MEK inhibition synergizes with TYK2 inhibitors in NF1-Associated malignant peripheral nerve sheath tumors","volume":"29","author":"Borcherding","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026072314213822800_oyag255-B27","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1007\/s00381-020-04731-2","article-title":"Current status of MEK inhibitors in the treatment of plexiform neurofibromas","volume":"36","author":"Gross","year":"2020","journal-title":"Childs Nerv Syst"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag255\/68691219\/oyag255.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag255\/68691219\/oyag255.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag255\/68691219\/oyag255.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T18:26:17Z","timestamp":1784831177000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag255\/8724137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag255","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,3]]},"article-number":"oyag255"}}